Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$9.46
-2.5%		$9.30
$3.92
▼
$19.15
$97.37M0.1253,990 shs23,966 shs
iBio, Inc. stock logo
IBIO
iBio
$1.42
-0.7%		$1.50
$0.76
▼
$3.82
$71.04M1.31778,745 shs513,075 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.50
+7.9%		$1.31
$0.81
▼
$2.46
$23.18M1.561,977 shs238,039 shs
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
$1.17
+3.5%		$1.20
$0.89
▼
$2.09
$77.72M-0.2458,026 shs56,356 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-2.47%+13.16%+19.75%-1.56%-23.34%
iBio, Inc. stock logo
IBIO
iBio
-0.70%-2.07%-0.70%-21.98%+141,999,900.00%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
+7.91%+29.31%+22.95%+3.45%+16.28%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
+3.54%+10.38%+1.74%-9.30%-19.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$9.46
-2.5%		$9.30
$3.92
▼
$19.15
$97.37M0.1253,990 shs23,966 shs
iBio, Inc. stock logo
IBIO
iBio
$1.42
-0.7%		$1.50
$0.76
▼
$3.82
$71.04M1.31778,745 shs513,075 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.50
+7.9%		$1.31
$0.81
▼
$2.46
$23.18M1.561,977 shs238,039 shs
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
$1.17
+3.5%		$1.20
$0.89
▼
$2.09
$77.72M-0.2458,026 shs56,356 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-2.47%+13.16%+19.75%-1.56%-23.34%
iBio, Inc. stock logo
IBIO
iBio
-0.70%-2.07%-0.70%-21.98%+141,999,900.00%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
+7.91%+29.31%+22.95%+3.45%+16.28%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
+3.54%+10.38%+1.74%-9.30%-19.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
2.00
Hold$9.500.42% Upside
iBio, Inc. stock logo
IBIO
iBio
3.13
Buy$5.00252.11% Upside
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
2.25
Hold$10.00566.67% Upside
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest MRKR, ATRA, TELO, and IBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/21/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/18/2026
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/6/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/31/2026
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/15/2026
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/2/2026
iBio, Inc. stock logo
IBIO
iBio
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
6/24/2026
iBio, Inc. stock logo
IBIO
iBio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/24/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/11/2026
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D) ➝ Sell (E+)
(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$120.77M0.79$4.75 per share1.99($5.34) per share-1.77
iBio, Inc. stock logo
IBIO
iBio
$400K176.36N/AN/A$0.90 per share1.58
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$3.55M7.04N/AN/A$1.01 per share1.49
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/AN/AN/AN/A$0.17 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$32.69M-$1.18N/A6.76N/A-269.42%-79.12%-73.01%10/29/2026 (Estimated)
iBio, Inc. stock logo
IBIO
iBio
-$18.38M-$0.58N/AN/AN/AN/A-53.86%-46.48%9/4/2026 (Estimated)
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$12.16M-$0.41N/AN/AN/A-343.03%-56.96%-47.82%11/12/2026 (Estimated)
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$10.41M-$0.91N/AN/AN/AN/A-102.70%-90.75%9/2/2026 (Estimated)

Latest MRKR, ATRA, TELO, and IBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/4/2026Q4 2026
iBio, Inc. stock logo
IBIO
iBio
-$0.07N/AN/AN/A$0.08 millionN/A
9/2/2026N/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$0.07N/AN/AN/AN/AN/A
8/14/2026Q2 2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$0.25-$0.09+$0.16-$0.09$0.68 millionN/A
8/13/2026Q2 2026
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$0.07-$0.79-$0.72-$0.79N/AN/A
8/12/2026Q2 2026
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$0.3150-$0.32-$0.0050-$0.32$0.55 million$0.63 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/AN/AN/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
N/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/AN/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/A
1.98
1.98
iBio, Inc. stock logo
IBIO
iBio
N/A
11.88
11.88
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/A
6.03
6.03
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/A
16.16
16.16

Institutional Ownership

CompanyInstitutional Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
70.90%
iBio, Inc. stock logo
IBIO
iBio
7.90%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
22.39%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
41.20%
iBio, Inc. stock logo
IBIO
iBio
2.75%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
5.70%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
16.36%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
33010.04 million5.90 millionNo Data
iBio, Inc. stock logo
IBIO
iBio
10049.68 million48.31 millionN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
6016.67 million15.72 millionNot Optionable
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
168.78 million57.52 millionN/A

Recent News About These Companies

Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telomir-pharmaceuticals-nasdaqtelo-releases-quarterly-earnings-results-2026-08-13/
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell?
August 12, 2026  |  defenseworld.netD
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% - Should You Sell?
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telomir-pharmaceuticals-nasdaqtelo-stock-price-down-34-should-you-sell-2026-08-12/
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/telomir-announces-peer-reviewed-publication-demonstrating-telomir-zn-suppresses-tumor-growth-in-tnbc-and-prostate-cancer-models-1036435451
Telomir-Zn Preclinical Data Support Advancement in TNBC
August 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-zn-preclinical-data-support-advancement-in-tnbc?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Preclinical Telomir-Zn Data Showing Tumor Suppression in Prostate and Triple-Negative Breast Cancer Models
August 10, 2026  |  quiverquant.comQ
TELO Telomir Pharmaceuticals, Inc.
July 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/TELO
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical ...
June 15, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/34770/telomir-pharmaceuticals-announces-peer-reviewed-publication-in-biomedicine-pharmacotherapy-demonstrating-restoration-of-insulin-sensitivity-with-telomir-zn-in-a-preclinical-type-2-diabetes-model/
Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data
June 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-showcases-preclinical-telomir-zn-diabetes-efficacy-data?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
June 15, 2026  |  accessnewswire.comA
Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change
June 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-appoints-fractional-cfo-after-leadership-change?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Inc TELO
May 26, 2026  |  morningstar.comM
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s Disease
May 20, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/32948/telomir-pharmaceuticals-reports-peer-reviewed-publication-of-telomir-zn-data-demonstrating-improved-survival-and-multiple-endpoint-benefits-in-wilsons-disease/
Telomir-Zn Preclinical Data Published in Wilson’s Disease
May 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-zn-preclinical-data-published-in-wilsons-disease?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
May 20, 2026  |  accessnewswire.comA
Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn
April 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-receives-fda-ind-clearance-for-telomir-zn?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
April 30, 2026  |  accessnewswire.comA
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
April 24, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/31216/telomir-pharmaceuticals-completes-acquisition-of-teli-pharmaceuticals-securing-global-rights-to-telomir-1-telomir-zn/
Telomir Pharmaceuticals Inc.
April 2, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/telo/research-ratings
Telomir seeks FDA approval for Telomir-1 to treat breast cancer
April 2, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/telomir-seeks-fda-approval-for-telomir-1-to-treat-breast-cancer/ar-AA1ZVLRj
Telomir Pharmaceuticals Regains Nasdaq Listing Rule Compliance
March 31, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-regains-nasdaq-listing-rule-compliance?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atara Biotherapeutics stock logo

Atara Biotherapeutics NASDAQ:ATRA

$9.46 -0.24 (-2.47%)
As of 08/24/2026 04:00 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

iBio stock logo

iBio NASDAQ:IBIO

$1.42 -0.01 (-0.70%)
Closing price 08/24/2026 04:00 PM Eastern
Extended Trading
$1.40 -0.02 (-1.41%)
As of 08/24/2026 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Marker Therapeutics stock logo

Marker Therapeutics NASDAQ:MRKR

$1.50 +0.11 (+7.91%)
Closing price 08/24/2026 04:00 PM Eastern
Extended Trading
$1.46 -0.04 (-3.00%)
As of 08/24/2026 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Telomir Pharmaceuticals stock logo

Telomir Pharmaceuticals NASDAQ:TELO

$1.17 +0.04 (+3.54%)
Closing price 08/24/2026 04:00 PM Eastern
Extended Trading
$1.15 -0.02 (-2.05%)
As of 08/24/2026 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas